Obiltoxaximab ELISA Kit

Introduction to Obiltoxaximab ELISA Kit

The Obiltoxaximab ELISA Kit is a highly sensitive and specific assay designed for the detection and quantification of obiltoxaximab, a monoclonal antibody used as a therapeutic agent against anthrax. This ELISA kit is a valuable tool for researchers and scientists in the field of biotechnology, pharmaceuticals, and immunology, providing a reliable and efficient method for the analysis of obiltoxaximab in various biological samples.

Structure of Obiltoxaximab

Obiltoxaximab is a fully human monoclonal antibody, with a molecular weight of approximately 148 kDa. It is composed of two heavy chains and two light chains, each containing a variable region and a constant region. The variable region of the antibody is responsible for binding to its target, while the constant region determines the antibody’s effector functions.

The structure of obiltoxaximab is based on the IgG1 isotype, making it a potent activator of the immune system. This antibody is produced using recombinant DNA technology, ensuring high purity and consistency in its structure and function.

Activity of Obiltoxaximab

Obiltoxaximab is a potent inhibitor of anthrax toxin, specifically targeting the protective antigen (PA) component. PA is a key component of the anthrax toxin, responsible for binding to host cells and facilitating the entry of the lethal factor (LF) and edema factor (EF) into the cell. By binding to PA, obiltoxaximab prevents the formation of the anthrax toxin complex, thereby neutralizing its toxic effects.

Obiltoxaximab has been shown to have a high affinity for PA, with a dissociation constant (Kd) of 0.1 nM. This high affinity allows for efficient binding and neutralization of the toxin, making it a highly effective therapeutic agent against anthrax.

Application of Obiltoxaximab ELISA Kit

The Obiltoxaximab ELISA Kit is a valuable tool for the quantification of obiltoxaximab in various biological samples, including serum, plasma, and tissue lysates. This assay utilizes a sandwich ELISA format, where the obiltoxaximab in the sample is captured by a monoclonal antibody coated on the surface of the ELISA plate. A second monoclonal antibody, conjugated with an enzyme, is then added to detect the captured obiltoxaximab. The intensity of the color produced is directly proportional to the amount of obiltoxaximab present in the sample, allowing for accurate and precise quantification.

The Obiltoxaximab ELISA Kit has a wide dynamic range, with a lower limit of detection (LOD) of 0.1 ng/mL and an upper limit of quantification (ULOQ) of 10 ng/mL. This high sensitivity and broad range make it suitable for a wide range of applications, including pharmacokinetic studies, drug development, and clinical trials.

In addition to its use in research and development, the Obiltoxaximab ELISA Kit also has potential applications in clinical settings. It can be used for monitoring obiltoxaximab levels in patients receiving treatment for anthrax infection, allowing for personalized dosing and optimization of therapy.

Conclusion

The Obiltoxaximab ELISA Kit is a valuable tool for the detection and quantification of obiltoxaximab, a monoclonal antibody used as a therapeutic agent against anthrax. Its high sensitivity, specificity, and broad dynamic range make it suitable for a wide range of applications, from research and development to clinical settings. With the growing threat of bioterrorism